Fratricide-resistant CD7-CAR T cells in T-ALL

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Relapsed or refractory T cell acute lymphoblastic leukemia (T-ALL) presents a significant clinical challenge with poor patient prognosis.
• Existing therapies often fall short for patients with advanced or resistant T-ALL.
• Chimeric antigen receptor (CAR) T cell therapy offers a novel approach to target hematologic malignancies.

Purpose of the Study:

• To evaluate the safety and efficacy of autologous anti-CD7 CAR T cells with a protein expression blocker (PEBL) in patients with relapsed/refractory T-ALL.
• To assess the impact of this therapy on remission rates, toxicity, and long-term outcomes.
• To investigate the mechanisms of CAR T cell persistence and immune reconstitution.

Main Methods:

• A case series of 17 patients with relapsed or refractory T-ALL received autologous anti-CD7 CAR T cells engineered with a PEBL to prevent fratricide.
• Patients received CAR T cells despite high leukemic burden and low dosing.
• Outcomes including remission, toxicity (cytokine release syndrome, neurotoxicity), relapse-free survival, and immune reconstitution were monitored.

Main Results:

• 16 out of 17 patients achieved minimal residual disease-negative complete remission within one month.
• Toxicities were generally mild, with grade 1-2 cytokine release syndrome and grade 1 immune effector cell-associated neurotoxicity syndrome observed.
• Eleven patients remained relapse-free at a median follow-up of 15 months, with one patient in remission for over 55 months.

Conclusions:

• Autologous anti-CD7 PEBL-CAR T cells demonstrate potent antileukemic activity in relapsed/refractory T-ALL.
• This CAR T cell therapy is a potentially effective and well-tolerated treatment option for challenging T-ALL cases.
• The therapy facilitates the emergence of functional, CD7-negative T cells, suggesting a path for immune recovery.